# A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

> **NCT05318976** · PHASE2 · COMPLETED · sponsor: **Inmune Bio, Inc.** · enrollment: 208 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
- Mild Cognitive Impairment

## Interventions

- **DRUG:** XPro1595
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05318976
- **Lead sponsor:** Inmune Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05318976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05318976, "A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05318976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*